StoneX Group Inc. Acquires New Shares in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

StoneX Group Inc. bought a new position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 18,882 shares of the company's stock, valued at approximately $755,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in HRMY. Citigroup Inc. boosted its holdings in Harmony Biosciences by 9.8% in the third quarter. Citigroup Inc. now owns 177,843 shares of the company's stock valued at $7,114,000 after acquiring an additional 15,859 shares during the last quarter. HealthInvest Partners AB increased its position in shares of Harmony Biosciences by 335.2% during the third quarter. HealthInvest Partners AB now owns 151,875 shares of the company's stock worth $6,075,000 after buying an additional 116,975 shares during the period. Massachusetts Financial Services Co. MA raised its stake in Harmony Biosciences by 27.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 660,391 shares of the company's stock worth $26,416,000 after buying an additional 140,690 shares during the last quarter. Intech Investment Management LLC bought a new stake in Harmony Biosciences during the third quarter valued at $388,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Harmony Biosciences in the 3rd quarter worth about $359,000. 86.23% of the stock is currently owned by institutional investors and hedge funds.

Harmony Biosciences Stock Up 1.9 %

Shares of NASDAQ HRMY traded up $0.64 during trading on Monday, hitting $34.71. The stock had a trading volume of 465,506 shares, compared to its average volume of 477,758. Harmony Biosciences Holdings, Inc. has a 12 month low of $28.14 and a 12 month high of $41.61. The company has a market capitalization of $1.98 billion, a PE ratio of 16.15, a PEG ratio of 0.63 and a beta of 0.77. The firm has a fifty day moving average of $35.53 and a two-hundred day moving average of $33.57. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its earnings results on Tuesday, October 29th. The company reported $0.79 earnings per share for the quarter, topping analysts' consensus estimates of $0.64 by $0.15. The firm had revenue of $186.00 million for the quarter, compared to the consensus estimate of $184.07 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The company's revenue was up 16.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.63 EPS. As a group, equities research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.36 EPS for the current fiscal year.

Insider Buying and Selling at Harmony Biosciences

In other news, insider Jeffrey Dierks sold 21,496 shares of the firm's stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $40.47, for a total transaction of $869,943.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 30.80% of the company's stock.

Analysts Set New Price Targets

HRMY has been the topic of several research analyst reports. Needham & Company LLC restated a "buy" rating and set a $52.00 target price on shares of Harmony Biosciences in a research report on Tuesday, October 29th. Raymond James restated an "outperform" rating and set a $40.00 price target on shares of Harmony Biosciences in a report on Thursday, October 10th. Cantor Fitzgerald lifted their price objective on shares of Harmony Biosciences from $51.00 to $58.00 and gave the company an "overweight" rating in a research note on Wednesday, October 30th. Mizuho increased their target price on shares of Harmony Biosciences from $42.00 to $52.00 and gave the stock an "outperform" rating in a research note on Thursday, October 10th. Finally, UBS Group assumed coverage on shares of Harmony Biosciences in a report on Tuesday, September 10th. They issued a "buy" rating and a $56.00 price target for the company. Two investment analysts have rated the stock with a sell rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $47.00.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.